BioSpace News Archive

Deals

Carisma and Sesen Bio Combine, Raise $30M for CAR-M Therapeutics (Updated)

Carisma Therapeutics is merging with Sesen Bio to advance Carisma’s cell therapy platform - in particular, its chimeric antigen receptor macrophage (CAR-M) therapies.

September 21, 2022
·
2 min read
·
Mark Terry
Biotech Bay

Remote Work Opportunities Abound at Pfizer, GRAIL, Regeneron and More

In a recent BioSpace poll, more than half of employers indicated they planned to continue recruiting employees remotely. We highlight just some of those jobs here.

September 21, 2022
·
5 min read
·
Lisa Munger
Business

Money on the Move: Marinus, Evotec, Ventyx and more (Updated)

This week’s money flowed into various therapeutic areas like cancer and inflammatory disorders, while government and philanthropic grants fund the fight against infectious diseases.

September 21, 2022
·
6 min read
·
Tristan Manalac
Drug Development

Poxel’s Positive Phase II Data Sparks More Momentum in NASH Space

Poxel presented positive histology data from its Phase II DESTINY-1 trial in non-alcoholic steatohepatitis (NASH), with its primary efficacy endpoint of liver fat decrease at 36 weeks.

September 21, 2022
·
3 min read
·
Mark Terry
Policy

J&J’s Talc Solution under Legal Review; Novartis Appeals to Supreme Court

A 3-judge panel questioned the legitimacy of Johnson & Johnson’s plan to form a subsidiary company with the purpose of absorbing legal liabilities from talc-related lawsuits.

September 21, 2022
·
3 min read
·
Alex Keown
Business

Novo Nordisk Doubles Down on Inflammatory Diseases, Quantum Computing

Novo Nordisk and Octagon Therapeutics announced that they forged a research collaboration focused on inflammatory diseases.

September 21, 2022
·
2 min read
·
Alex Keown
Drug Development

Celltrion/Abpro, Merck/Nerviano and more Unite against Cancer

Celltrion agreed Wednesday to jointly develop Abpro’s cancer molecule ABP-102 in a deal that could net as much as $1.75 billion. See inside for more cancer collaborations.

September 21, 2022
·
2 min read
·
Paul Elias
Drug Development

Merck Resumes Trials on HIV Hopeful, But Drops PrEP Bid For Now

After enduring nine months of clinical holds, Merck announced that it is restarting the Phase III clinical program for islatravir, its candidate for people with HIV-1 infection.

September 21, 2022
·
3 min read
·
Tristan Manalac
Pharm Country

Centinel Spine® Announces First Commercial Use of the prodisc® C Vivo Cervical Total Disc Replacement System in the Western U.S.

Centinel Spine®, LLC, a leading global medical device company addressing cervical and lumbar spinal disease through anterior surgical access, today announced the first implantation of its prodisc® C Vivo Cervical Total Disc Replacement (TDR) product in the Western U.S.

September 21, 2022
·
3 min read
BioMidwest

C₂N Diagnostics Partners with Grupo Fleury to Bring Pioneering Blood Tests to Brazil for Advancing Brain Health

C2N Diagnostics announced it has entered a partnership with Grupo Fleury, one of Brazil’s leading healthcare companies, to bring blood-based tests that aid in early Alzheimer’s diagnosis to patient care in Brazil.

September 21, 2022
·
5 min read